Phase 2 N=309 A Study of ALKS 3831 in Adults With Schizophrenia
Schizophrenia
Primary: Absolute Change in Total Positive and Negative Syndrome Scale (PANSS) Score — -2.9; -1.5; -2.7; -2.5 units on a scale — p=0.3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 Feasibility Study of Metformin Therapy in ADPKD
Polycystic Kidney, Autosomal Dominant
Primary: Safety and Tolerability of Metformin — 50; 100; 82; 100 percentage of participants
Phase 2 N=376 Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds
Meningitis, Meningococcal
Primary: Severe Solicited Adverse Event — 0; 0; 0; 0 participants
Phase 2 N=23 Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Breast Cancer
Primary: Percentages of Participants With Pathologic Complete Response — 48 percentage of participants
Phase 2 N=31 Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: A Pilot and Feasibility Study
Brain Injuries · Wounds and Injuries · Hemorrhage
Primary: Pediatric Quality of Life Inventory (PedsQL) — 64.9; 60.2; 67.2 Quality of life units * months
Phase 2 N=118 Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Prostate Cancer
Primary: Combined pCR or MRD Rate [Part 1] — 12; 12 Participants
Phase 2 N=289 Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · Leukemia
Primary: Number of Participants With Complete Remission (CR) — 185 Participants
Phase 2 N=20 A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret
Hepatitis C
Primary: Number of Incidences of Viremia After Receiving a Lung Transplant From a Donor Who Tests Positive for Hepatitis C — 16 incidences
Phase 2 N=38 High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML
Acute Myeloid Leukemia, in Relapse
Primary: The Rate of Complete Remission (CR) — 14 Participants
Phase 2 N=149 A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
Phobic Disorders
Primary: Change From Baseline in Liebowitz Social Anxiety Scale (LSAS) Total Score — -22.4; -29.4 units on a scale
Phase 2 N=214 A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
Platinum-Sensitive Ovarian Cancer in First Relapse
Primary: Progression Free Survival (PFS) — 11.73; 10.78 Months
Phase 2 N=25 Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Acute Leukemia · Chronic Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants Experiencing Relapse or Progression — 10 Participants
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
Phase 2 N=25 Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Two-year Relapse Free Survival of Patients — 8; 1; 1 Participants
Phase 2 N=56 Cantharidin and Occlusion in Verruca Epithelium
Common Wart · Warts Hand · Warts
Primary: Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) — 4 Participants